Bahaa Jabali Ph.D., Postdoctoral Researcher
Bahaa Jabali Ph.D., Postdoctoral Researcher
Education
2026–Present: Postdoctoral Researcher, Medicinal Chemistry Department, University of Kansas, Lawrence, KS, USA
2021–2025: Ph.D. in Pharmaceutical Sciences (Medicinal Chemistry), University of Arkansas for Medical Sciences, Little Rock, AR, USA
2023–2024: Graduate Certificate in Regulatory Sciences, University of Arkansas for Medical Sciences, Little Rock, AR, USA
2010–2014: M.Sc. in Applied Chemistry, Birzeit University, Ramallah, Palestine
2000–2005: B.Sc. in Pharmacy, An-Najah National University, Nablus, Palestine
Contact Information
Email: bahaajabali@ku.edu
LinkedIn: https://www.linkedin.com/in/bahaa-jabali-812048180
Google Scholar: https://scholar.google.com/citations?user=D2U9oB4AAAAJ&hl=en
Research keywords: Medicinal chemistry, drug discovery, small molecule drug design, tyrosine kinase inhibitors, structure–activity relationships, lead optimization, targeted protein degradation (PROTACs), DNA–protein crosslinking, chemical biology, oncology drug development
Biography: Bahaa Jabali is a medicinal chemist with over 16 years of experience in pharmacy practice, including leadership roles as a pharmacy manager and pharmacy owner, before transitioning into academic research in medicinal chemistry. His research focuses on the design and synthesis of small molecules for cancer therapy, with an emphasis on targeted inhibition and protein degradation strategies. During his Ph.D., he developed next-generation inhibitors targeting EGFR and RET kinases to overcome drug resistance in non-small cell lung cancer, combining synthetic chemistry with biological evaluation to optimize therapeutic candidates.
In 2026, he joined Dr. Luke Erber’s research group at the University of Kansas as a postdoctoral researcher. His current work focuses on DNA–protein crosslinking (DPC) chemistry, where he designs and studies chemical probes to investigate DNA damage and repair mechanisms, with the goal of advancing their therapeutic applications in cancer biology.